SCHEMBL4083024

SCHEMBL4083024

Cc1ccc(-n2c(Cl)nc3ccccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.55
HTT P42858 4/20 0.54
MAPK1 P28482 2/20 0.54
ESR1 P03372 3/20 0.49
ESR2 Q92731 3/20 0.49
LMNA P02545 4/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TP53 P04637 2/20 0.46
PTGS2 P35354 1/20 0.44
RAB9A P51151 2/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095150 0.86 SMN1; SMN2 (0.53) SMN1; SMN2HTTMAPK1ESR1ESR2
SCHEMBL12730136 0.85 MAPK1 (0.61) L3MBTL1SMN1; SMN2HTTMAPK1ESR1
SCHEMBL20603917 0.83 SMN1; SMN2 (0.50) SMN1; SMN2HTTMAPK1ESR1ESR2
SCHEMBL9995277 0.83 SMN1; SMN2 (0.50) L3MBTL1SMN1; SMN2HTTMAPK1ESR1
SCHEMBL18731715 0.83 ESR1 (0.54) L3MBTL1SMN1; SMN2HTTMAPK1ESR1
SCHEMBL7760076 0.82 MAPK1 (0.79) L3MBTL1SMN1; SMN2HTTMAPK1ESR1
SCHEMBL4096979 0.82 RPS6KB1 (0.54) L3MBTL1SMN1; SMN2HTTMAPK1LMNA
SCHEMBL13231714 0.79 ESR2 (0.67) L3MBTL1HTTMAPK1ESR1ESR2
SCHEMBL1104437 0.79 L3MBTL1 (0.56) L3MBTL1SMN1; SMN2HTTMAPK1ESR1
SCHEMBL15214855 0.79 L3MBTL1 (0.56) L3MBTL1SMN1; SMN2HTTMAPK1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2009-03-05 US disclosed
EP-1778670-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM Pharma A/S (DK) 2007-05-02 EP disclosed
WO-2006010446-A2 MEDICINAL USE OF RECEPTOR LIGANDS 7TM PHARMA A/S (DK) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062317-A1 MEDICINAL USE OF RECEPTOR LIGANDS MCHR1, MCHR2, MC1R L3MBTL1 663/4885SMN1; SMN2 2987/4885HTT 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.